EVIDENCE FOR A 1,2-HYDRIDE SHIFT IN THE MICROSOMAL METABOLISM OF THE HETEROCYCLE L-158,338, A NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST

被引:0
|
作者
STEARNS, RA
MILLER, RR
ARISON, BH
ROSEGAY, A
SMITH, JL
MANTLO, NB
CHIU, SHL
机构
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
L-158,338 is an imidazo[4,5-b]pyridine derivative that is a potent and highly selective angiotensin II receptor antagonist. Rat liver microsomal metabolism of [C6-H-3]L-158,338 gave a major metabolite that was monohydroxylated at the C6 position of the imidazo-pyridine but showed partial retention of the radiolabel. This biotransformation necessitated a shift of the radiolabel from the C6 position to another site within the molecule. We have investigated the mechanism of this biotransformation using H-3-, H-3/C-14-, and H-2-labeled L-158,338. Metabolites were identified by FAB/MS, LC/MS, and H-1-NMR. Results of these studies show that the microsomal metabolism of L-158,338 to its C6-monohydroxylated derivative was mediated by a 1,2 hydride shift.
引用
收藏
页码:670 / 676
页数:7
相关论文
共 39 条
  • [31] IN-VITRO N-GLUCURONIDATION OF SR-47436 (BMS-186295), A NEW AT1 NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST, BY RAT, MONKEY AND HUMAN HEPATIC-MICROSOMAL FRACTIONS
    PERRIER, L
    BOURRIE, M
    MARTI, E
    TRONQUET, C
    MASSE, D
    BERGER, Y
    MAGDALOU, J
    FABRE, G
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1994, 271 (01): : 91 - 99
  • [32] Effect of the novel angiotensin II type 1 receptor antagonist L-158,809 on acute infarct expansion and acute anterior myocardial infarction in the dog
    Ford, WR
    Khan, MI
    Jugdutt, BI
    CANADIAN JOURNAL OF CARDIOLOGY, 1998, 14 (01) : 73 - 80
  • [33] Effect of a novel angiotensin II type 1 (AT1) receptor antagonist (L-158,809) on hemodynamics and early LV remodeling after canine myocardial infarction
    Jugdutt, BI
    Khan, MI
    CIRCULATION, 1996, 94 (08) : 3647 - 3647
  • [34] IN-VIVO LABELING OF ANGIOTENSIN-II RECEPTORS WITH [C-11] L-159,884, AN AT1 SUBTYPE-SELECTIVE NONPEPTIDE ANTAGONIST
    KIM, SE
    SCHEFFEL, U
    SZABO, Z
    BURNS, HD
    GIBSON, RE
    RAVERT, HT
    MATHEWS, WB
    HAMILL, TG
    DANNALS, RF
    JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (05) : P52 - P52
  • [35] The Effect of an Angiotensin II AT1 Receptor Antagonist, L-158,809, on Baroreflex Sensitivity in Conscious Two-kidney, One-clip Hypertensive Rats
    Ozaykan, Besim
    Kocakli, Zehra Gul
    ACTA PHYSIOLOGICA, 2016, 218 : 15 - 15
  • [36] PREVENTION OF THROMBOXANE-A2 (TXA2) RECEPTOR-MEDIATED PULMONARY-HYPERTENSION AND PLASMA EXUDATION BY A NONPEPTIDE ANGIOTENSIN-II TYPE-1 (AT1) RECEPTOR ANTAGONIST
    VALENTIN, JP
    BERTOLINO, F
    MAFFRE, M
    JOVER, B
    BESSAC, AM
    JOHN, GW
    HYPERTENSION, 1993, 22 (03) : 441 - 441
  • [37] Inhibitory effects of a subdepressor dose of L-158,809, an angiotensin II type 1 receptor antagonist, on cardiac hypertrophy and nephropathy via the activated human renin-angiotensin system in double transgenic mice with hypertension
    Kai, T
    Sugimura, K
    Shimada, S
    Kurooka, A
    Takenaka, T
    Ishikawa, K
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1998, 62 (08): : 599 - 603
  • [38] X-6803 (METHYL 2-N-BUTYL-1-[4-(2-CARBOXYBENZAMIDO) BENZYL]-4-CHLOROIMIDAZOLE-5-ACETATE, SODIUM-SALT) - A NOVEL NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST
    WONG, PC
    PRICE, WA
    CHIU, AT
    THOOLEN, MJMC
    DUNCIA, JV
    JOHNSON, AL
    TABER, RI
    TIMMERMANS, PBMWM
    HYPERTENSION, 1988, 12 (03) : 340 - 340
  • [39] SYNTHESIS OF [C-14] KT3-671, 2-PROPYL-8-OXO-1-[(2'-(1H-[C-14]TETRAZOLE-5-YL) BIPHENYL-4-YL)METHYL]-4,5,6,7-TETRAHYDRO-CYCLOHEPTIMIDAZOLE, A NOVEL POTENT NONPEPTIDE ANGIOTENSIN-II RECEPTOR ANTAGONIST
    UEYAMA, N
    YANAGISAWA, T
    TOMIYAMA, T
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 1995, 36 (10): : 915 - 919